Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction

Anti-Cancer Drugs

Volumn 16, Issue 4, 2005, Pages 381-391

  Tudor, Gabriela ^a   Alley, Mike ^b   Nelson, Christopher M ^c   Huang, Ruili ^b   Covell, David G ^b   Gutierrez, Peter ^d   Sausville, Edward A ^d,e  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antitumor; Apoptosis; Aziridinylbenzoquinones; Free radicals; NQO1; Redox cycling

Indexed keywords

1,4 BENZOQUINONE DERIVATIVE; 2,5 DIAZIRIDINYL 3 (HYDROXYMETHYL) 6 METHYL 1,4 BENZOQUINONE; DICOUMAROL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SUBSTRATE; ENZYME THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA; MYELOID LEUKEMIA; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

APOPTOSIS; AZIRIDINES; BENZOQUINONES; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICALS; HL-60 CELLS; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); OXIDATION-REDUCTION; OXIDATIVE STRESS; OXYGEN; TIME FACTORS; TRANSFECTION;

EID: 15944374319     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200504000-00004     Document Type: Article

References (43)

1. Ernster L. DT-diaphorase. Methods Enzymol 1967; 10:309-317.
2. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990; 50:7483-7489.
3. Gibson NW, Hartley JA, Butler J, Siegel D, Ross D. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity. Mol Pharmacol 1992; 42:531-536.
4. Ross D, Siegel D, Beall HD, Prakash AS, Mulcahy RT, Gibson NW. DT-diaphorase in activation and detoxification of quinines. Bioreductive activation of mitomycin C. Cancer Metastasis Rev 1993; 12:83-101.
5. Walton MI, Bibby MC, Double JA, Plumb JA, Workman P. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer 1992; 28A:1597-1600.
6. Gan Y, Mo Y, Kalns JE, Lu J, Danenberg K, Danenberg P, Wientjes MG, et al. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity and human bladder tumors. Clin Cancer Res 2001; 7:1313-1319.
7. Wang X, Doherty G, Leith M, Curphey T, Begleiter A. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer 1999; 80:1223-1230.
8. Siegel D, Hartman C, Beall H, Kasai M, Arai H, Gibson NW, et al. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 1992; 31;7879-7885.
9. Beall HD, Yafei L, Siegel D, Gibson NW, Ross D. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem Pharmacol 1996; 51:645-652.
10. Cummings J, Ritchie A, Butler J, Ward TH, Langdon S. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts. Anticancer Res 2003; 23:3979-3983.
11. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of diaziquone (AZQ) by NAD(P)H: (quinone-acceptor) oxidoreductase (DT-diaphorase): role in AZQ-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990; 50:7293-7300.
12. Fisher GR, Gutierrez PL. The reductive metabolism of diaziquone (AZQ) in the S9 fraction of MCF-7 cells: free radical formation and NAD(P)H:quinone- acceptor oxidoreductase (DT-diaphorase) activity. Free Rad Biol Med 1991; 10:359-370.
13. Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 1991; 42:1021-1027.
14. Jarrett CM, Bibby MC, Phillips RM. Bioreductive enzymology of malignant and normal human tissues. Proc Am Ass Cancer Res 1998; 39:429-436.
15. Beall HD, Murphy AM, Siegel D, Hargreaves RHJ, Butler J, Ross D. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 1995; 48:499-504.
16. Winski SL, Hargreaves RHJ, Butler J, Ross D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res 1998; 4:3083-3088.
17. Dehn DL, Winski SL, Ross D. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1. Clin Cancer Res 2004; 10:3147-3155.
18. Khan P, Abbas S, Hargreaves HJ, Caffrey R, Megram V, McGown A. Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatographic assay for the novel bio-reductive antitumor agent RH1 in human and mouse plasma. J Chromatogr B 1999; 729: 287-295.
19. Loadman PM, Phillips RM, Lim LE, Bibby MC. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl- 1,4-benzoquinone), in mice. Biochem Pharmacol 2000; 59: 831-837.
20. Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S, Workman P. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 2000; 58:1146-1155.
21. Faing M, Bianchet MA, Winski S, Hargreaves R, Moody CJ, Hudnott RA, et al. Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones. Structure 2001; 9:659-667.
22. Winski SL, Swann E, Hargreaves RHJ, Dehn DL, Butler J, Moody CJ, et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 2001; 61:1509-1516.
23. Cheung AP, Struble E, Nguyen N, Liu P. Stability-indicating HPLC assay and solution stability of a new diaziridinyl benzoquinone. J Pharm Biochem Anal 2001; 24:957-966.
24. Elliot MA, Ford SJ, Walker AA, Hargreaves RHJ, Halbert GW. Development of a lyophilised RH 1 formulation: a novel DT diaphorase activated alkylating agent. Pharm Pharmacol 2001; 54:487-492.
25. Nemeikaite-Ceniene AN, Sarlauskas J, Anusevicius Z, Nivinskas H, Cenas N. Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H:quinone oxidoreductase (NQO1) and oxidative stress. Arch Biochem Biophys 2003; 416:110-118.
26. Hargreaves RHJ, Hartley JA, Butler J. Mechanisms of action of quinone-containing alkylating agents aziridinylquinones. Front Biosci 2000; 5: 172-180.
27. Xing C, Skibo EB. Sigmatropic reactions of the aziridinyl semiquinone species. Why aziridinyl benzoquinones are metabolically more stable than aziridinyl indoloquinones. Biochemistry 2000; 39:10770-10780.
28. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996; 88:259-269.
29. Phillips RM. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] pro-beta-en-alpha-ol (EO9) by human DT-diaphorase. Biochem Pharmacol 1996; 52:1711-1718.
30. Tudor G, Gutierrez P, Aguilera-Gutierrez A, Sausville EA. Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression. Biochem Pharmacol 2003; 65:1061-1075.
31. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83:757-766.
32. Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA. The NCI anticancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des 1997; 12:533-541.
33. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor lines using a microculture tetrazolium assay. Cancer Res 1988; 48:589-601.
34. Alley MC, Pacula-Cox CM, Hollingshead MG, Camalier RF, Mayo JG, Plowman J, et al. Utility of a PVDF filter plate assay to facilitate selection of tumor cell lines for in vivo drug testing. Proc Am Ass Cancer Res 1995; 36:305.
35. Hollingshead MG, Alley MC, Kaur G, Pacula-Cox CM, Stinson SF. Specialized in vitro/in vivo procedures employed by NCI In pre-clinical drug evaluations. In: Teacher BA, Andrews P (editors): Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, 2nd edn. Totowa, NJ: Humana Press; 2005, in press.
36. Powis G. Metabolism and reactions of quinoid anticancer agents. Pharmacol Ther 1987; 35:57-162.
37. Gutierrez PL. The metabolism of quinone-containing alkylating agents: free radical production and measurement. Front Biosci 2000; 5:629-638.
38. Mossoba MM, Alizadeh M, Gutierrez PL. Mechanism for the reductive activation of Diaziquone. J Pharm Sci 1985; 74:1249-1254.
39. Soldani C, Lazze MC, Bottone MG, Tognon G, Biggiogera M, Pellicciari CE, et al. Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where? Exp Cell Res 2001; 269:193-201.
40. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 2001; 8:739-761.
41. Fourie J, Guziec Jr F, Guziec L, Monterrosa C, Fiterman DJ, Begleiter A. Structure-activity study with bioreductive benzoquinon alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanism of cytotoxicity. Cancer Chemother Pharmacol 2004; 53:191-203.
42. Tang DG, Zhenyu Zhu LL, Joshi B. Apoptosis in the absence of cytochrome c accumulation in the cytosol. Biochem Biophys Res Commun 1998; 242:380-384.
43. Inayat-Hussain SH, Winski SL, Ross D. Differential involvement of caspases in hydroquinone-induced apoptosis in human leukemic HL-60 and Jurkat cells. Toxicol Appl Pharmacol 2001; 175:95-103.